Meiji Yasuda Life Insurance Co Has $774,000 Position in Mylan (MYL)

Meiji Yasuda Life Insurance Co Has $774,000 Position in Mylan (MYL)

Other large investors have also made changes to their positions in the company. State Street Corp increased its stake in Mylan by 7.8% in the fourth quarter. State Street Corp now owns 19,942,043 shares of the company’s stock worth $760,788,000 after buying an additional 1,446,244 shares during the last quarter. Bank of The West increased its stake in Mylan by 4.9% in the first quarter. Bank of The West now owns 72,582 shares of the company’s stock worth $2,830,000 after buying an additional 3,360 shares during the last quarter. Wade G W & Inc. increased its stake in Mylan by 3.6% in the first quarter. Wade G W & Inc. now owns 6,156 shares of the company’s stock worth $240,000 after buying an additional 213 shares during the last quarter. Intact Investment Management Inc. increased its stake in Mylan by 34.4% in the fourth quarter. Intact Investment Management Inc. now owns 30,100 shares of the company’s stock worth $1,148,000 after buying an additional 7,700 shares during the last quarter. Finally, Baird Financial Group Inc. increased its stake in Mylan by 10.0% in the first quarter. Baird Financial Group Inc. now owns 756,355 shares of the company’s stock worth $29,490,000 after buying an additional 68,967 shares during the last quarter. 60.89% of the stock is currently owned by institutional investors.

Meiji Yasuda Life Insurance Co held its stake in shares of Mylan (NASDAQ:MYL) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,849 shares of the company’s stock at the end of the first quarter. Meiji Yasuda Life Insurance Co’s holdings in Mylan were worth $774,000 at the end of the most recent reporting period.

Mylan (NASDAQ:MYL) opened at 39.36 on Wednesday. The firm has a 50-day moving average price of $38.12 and a 200 day moving average price of $38.90. The firm has a market capitalization of $21.09 billion, a P/E ratio of 39.32 and a beta of 1.14. Mylan has a one year low of $33.60 and a one year high of $50.40.

Mylan (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, May 10th. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.92 by $0.01. The business had revenue of $2.72 billion during the quarter, compared to the consensus estimate of $2.81 billion. Mylan had a net margin of 2.50% and a return on equity of 22.04%. The firm’s quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.76 EPS. Equities research analysts anticipate that Mylan will post $5.18 earnings per share for the current year.

A number of equities research analysts have recently issued reports on MYL shares. Barclays PLC upgraded shares of Mylan from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $47.00 to $50.00 in a research report on Monday, May 22nd. Zacks Investment Research upgraded shares of Mylan from a “sell” rating to a “hold” rating in a research report on Monday, February 27th. Vetr downgraded shares of Mylan from a “buy” rating to a “sell” rating and set a $43.36 price target for the company. in a research report on Wednesday, March 1st. Royal Bank of Canada reiterated a “sector perform” rating and set a $46.00 price target (down from $48.00) on shares of Mylan in a research report on Monday, April 17th. Finally, BMO Capital Markets started coverage on shares of Mylan in a research report on Monday, May 1st. They set an “outperform” rating and a $50.00 price target for the company. One research analyst has rated the stock with a sell rating, nine have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Mylan currently has an average rating of “Buy” and a consensus target price of $51.28.

In related news, major shareholder Laboratories Abbott sold 44,000,000 shares of the company’s stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $41.60, for a total value of $1,830,400,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.71% of the stock is currently owned by corporate insiders.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:MYL”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).

Related posts

Leave a Comment